Grants for Public and State controlled institutions of higher education - Science and Technology

This funding opportunity provides financial support to cancer researchers at the IU Simon Comprehensive Cancer Center whose NIH grant applications were close to being funded but fell short of the payline.

The "ROSES 2024: A.21 TEMPO/ACX Science and Applications Team" grant is a funding opportunity released by NASA's Science Mission Directorate for a wide range of basic and applied research in space and Earth sciences, with the aim to support projects through grants, cooperative agreements, contracts, and inter- or intra-agency transfers, depending on the nature of the proposed work.

This grant provides funding and support to early-stage U.S. startups developing innovative technologies that can meet critical needs of the Department of Defense.

This program provides funding for researchers and innovators to develop advanced technologies for rapidly identifying and sequencing complex protein-based biothreats, enhancing national security and defense capabilities.

This funding opportunity supports innovative research and development projects aimed at improving STEM education for students and teachers in pre-kindergarten through grade 12 across various educational organizations.

This grant provides $2 million over two years to research teams focused on developing innovative methods for the early detection and diagnosis of hard-to-treat cancers with low survival rates.

The Mayor’s Office of Community Development is offering grants of up to $10,000 for MLK Day of Service Community Projects. This initiative aligns with the foundation's mission to honor Dr. Martin Luther King Jr.’s legacy. The program's core objective is to promote community service, advance social justice, and address essential community needs, reflecting a commitment to the principles Dr. King championed. The target beneficiaries for these grants include non-profit organizations, educational institutions, faith-based organizations, and businesses located in Louisiana. Projects must be situated in low to moderate-income areas, as defined by Housing Urban Development (HUD), ensuring that the grants directly benefit communities with the greatest needs. The overarching impact goal is to foster positive change and equitable development within these communities. The program prioritizes projects that embody Dr. King’s legacy, focusing on activities that promote community engagement and social justice. This includes initiatives that address critical community needs, indicating a preference for projects with tangible and immediate benefits for residents. The selection criteria emphasize the applicant's good standing with the City of Baton Rouge and the Secretary of State, ensuring accountability and effective project implementation. Expected outcomes include an increase in community service activities, enhanced social justice initiatives, and a measurable improvement in essential community needs within the targeted low to moderate-income areas. While specific measurable results are not explicitly detailed beyond the "up to $10,000" grant size, the focus on addressing "essential community needs" suggests that successful projects will demonstrate clear, positive impacts on their communities. The foundation's strategic priority is to invest in community-led solutions that align with a theory of change centered on empowering local organizations to drive social progress and honor Dr. King's enduring message.

This grant option, part of the Minnesota Spinal Cord Injury and Traumatic Brain Injury Research Grant Program, aims to support early-stage research into innovative treatments and rehabilitative techniques for spinal cord and traumatic brain injuries. The Tier 1 Pilot Project Grant does not require preliminary data but encourages it, reflecting early investment as researchers prepare to seek larger grants. The funding amount can reach up to $125,000 for a project duration of two years with an additional one-year no-cost extension.

This grant provides funding to researchers and institutions to enhance their capabilities in conducting high-quality STEM education research, focusing on improving learning environments, broadening participation, and developing the STEM workforce.

The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the best and brightest in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research.As the intent of the Era of Hope Scholar Award is to recognize creative and innovative individuals rather than projects, the central features of the award are the demonstrated ability of the individual named as the Principal Investigator (PI) in the application to go beyond conventional thinking in their field and the innovative contribution that the PI can make toward ending breast cancer. The application should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must commit a minimum of 25% level of time and effort during the period of performance to conduct breast cancer research under this award. Individuals from other disciplines who apply novel concepts to breast cancer are encouraged to submit.The PI is encouraged to assemble a research team that will provide the necessary expertise and collaborative efforts toward accomplishing the research goals. The PIs research team must include two or more breast cancer consumer advocates. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization. Their role should be independent of their employment, and they may not be employees of any organizations participating in the application. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project. Their role should be focused on providing objective input throughout the research effort and its potential impact for individuals with, or at risk for, breast cancer.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women’s health outcomes and/or advancing knowledge for women’s health.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Clinical trials are allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 Era of Hope Scholar Award should not exceed $3.5M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $5.4M to fund approximately one Era of Hope Scholar Award application. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports U.S. scientists collaborating with researchers in developing countries to address agricultural, energy, and environmental challenges through equitable partnerships in plant genome research.

This grant provides funding for innovative research on brain and nervous system disorders, encouraging collaboration between U.S. and low- and middle-income country researchers to improve global health outcomes.

This grant provides financial support to Oklahoma-based educational institutions, state agencies, and trade groups to advance the state's grape and wine industries through research, education, product development, and marketing initiatives.

This grant provides funding to California-based researchers, universities, government agencies, and nonprofits to develop innovative pest management strategies for addressing invasive agricultural pests.

This grant provides funding to early-career researchers focused on developing and applying Earth system models to address urgent climate challenges and promote diversity and inclusion in climate science.

EPoC – Entrepreneurial Proof of Concept o Supports proof of concept research towards establishing a new Delaware-based business by the end of the grant period. o Up to $75,000 for 1 year . Proposal must be submitted as a single electronic PDF document at the link provided on the CAT website https://cat.dbi.udel.edu. Please note that submission and award processes have changed.Proposal must be submitted as a single electronic PDF document at the link provided on the CAT website https://cat.dbi.udel.edu. Please note that submission and award processes have changed.

The FY24 DMDRP CTRA mechanism supports advanced translational research that will accelerate the movement of promising ideas in DMD research into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. However, applicants should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between applied and clinical research. As such, applications must include preliminary and/or published data relevant to DMD to support the proposed research project.This mechanism is intended to support established projects that have moved beyond the realm of basic research and proof of concept studies and have the potential to result in a near-term impact in clinical research or the clinic. Research projects investigating therapies that will be efficacious across the life span, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged. Pilot, proof-of-principle clinical trials, and correlative studies to better inform development of drugs, devices, and other interventions are allowed.Early-Career Partnering PI Option: The FY24 DMDRP encourages applications that include meaningful and productive collaborations between investigators. In an effort to promote enhanced research capacity within the DMD field, the FY24 CTRA includes an option for an Early-Career Partnering Principal Investigator (PI). The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Early-Career PI will be identified as the Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.The FY24 DMDRP CTRA offers two funding levels (refer to Section II.D.5 Funding Restrictions). Only one funding level category may be chosen per application, and the choice of application category is at the discretion of the applicant. The following are generalized descriptions of the scope of the research appropriate for each funding level:Funding Level 1: Funding Level 1 is intended to support smaller, less complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $650,000.Funding Level 2: Funding Level 2 is intended to support larger, more complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $1.35M.Additionally, both funding levels will support an Early-Career Partnering PI Option at the same maximum direct costs and periods of performance, respectively.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Both pilot clinical trials and clinical research are permitted under this mechanism.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.All investigators applying to FY24 DMDRP funding opportunities and conducting clinical research are encouraged to consult the Strategies to Promote Diversity in Muscular Dystrophy Research Participation developed by the MDCC.

The Preschool Development Grant is a three-year federal initiative designed to bolster Delaware's early childhood system, ensuring it is inclusive and integrated to support the development and learning of all children and their families from birth through age 5. With an $8 million award for its first year, following a $4.2 million PDG B-5 grant received in December 2018, the grant aims to provide high-quality early learning experiences and facilitate a smooth transition to kindergarten for children. Approximately $4.8 million of the grant is allocated to expand home-visiting services and state-funded preschool seats, while $3.2 million is dedicated to enhancing support for professionals, including technological advancements delayed by the pandemic. Key initiatives funded by the grant include expanding state-funded preschool programs, piloting the Family Connects home visiting model, updating family materials for resource and referral, enhancing workforce support for early childhood professionals, developing a mental health consultation program for home visitors, and updating the state’s strategic plans for a cohesive birth to five strategy.

This funding opportunity supports doctoral students and research teams in California to conduct inclusive precision medicine research that addresses health disparities among historically underrepresented populations.

This funding opportunity supports researchers conducting in-depth studies on job quality and labor market changes in the U.S., particularly in relation to technology and economic shifts.